Friday, January 12, 2018 -- But obesity (MedPage Today) -- with or without psoriasis -- ups pediatric risks even more
Tuesday, January 16, 2018 -- Novartis has released trial data showing that Cosentyx was “significantly more effective” than Johnson & Johnson’s rival biologic Stelara in achieving clear skin in patients with psoriasis.
Wednesday, January 17, 2018 -- NewsResults from the CLARITY study show Cosentyx (secukinumab) was significantly more effective than Stelara (ustekinumab) in delivering clear and almost clear skin at 12 weeks and at 16 weeks.Contributed Author: Novartis Pharmaceuticals CorporationTopics: Drug Development
Tuesday, January 16, 2018 -- Fresh data support Cosentyx's superiority to Stelara in treating plaque psoriasis.
Thursday, January 11, 2018 -- Those with psoriasis at higher risk for diabetes, liver disease, elevated lipid levels independent of obesity
Wednesday, January 17, 2018 -- Case report: After initiation of ledipasvir-sofosbuvir, HCV RNA decreased, and skin lesions improved
Thursday, January 18, 2018 -- (MedPage Today) -- Meta-analysis compares three classes of treatment head to head